DaVita Long Term Debt 2010-2024 | DVA

DaVita long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
  • DaVita long term debt for the quarter ending March 31, 2024 was $9.001B, a 6.93% increase year-over-year.
  • DaVita long term debt for 2023 was $8.268B, a 4.88% decline from 2022.
  • DaVita long term debt for 2022 was $8.693B, a 0.42% decline from 2021.
  • DaVita long term debt for 2021 was $8.729B, a 10.25% increase from 2020.
DaVita Annual Long Term Debt
(Millions of US $)
2023 $8,268
2022 $8,693
2021 $8,729
2020 $7,917
2019 $7,978
2018 $8,173
2017 $9,158
2016 $8,945
2015 $9,001
2014 $8,299
2013 $8,141
2012 $8,327
2011 $4,418
2010 $4,234
2009 $3,532
DaVita Quarterly Long Term Debt
(Millions of US $)
2024-03-31 $9,001
2023-12-31 $8,268
2023-09-30 $8,285
2023-06-30 $8,598
2023-03-31 $8,418
2022-12-31 $8,693
2022-09-30 $8,867
2022-06-30 $9,065
2022-03-31 $8,687
2021-12-31 $8,729
2021-09-30 $8,771
2021-06-30 $8,798
2021-03-31 $8,830
2020-12-31 $7,917
2020-09-30 $7,867
2020-06-30 $7,895
2020-03-31 $8,442
2019-12-31 $7,978
2019-09-30 $8,014
2019-06-30 $5,378
2019-03-31 $5,787
2018-12-31 $8,173
2018-09-30 $8,441
2018-06-30 $8,176
2018-03-31 $9,280
2017-12-31 $9,158
2017-09-30 $8,909
2017-06-30 $8,911
2017-03-31 $8,919
2016-12-31 $8,945
2016-09-30 $8,972
2016-06-30 $8,957
2016-03-31 $8,980
2015-12-31 $9,001
2015-09-30 $9,082
2015-06-30 $9,101
2015-03-31 $8,380
2014-12-31 $8,299
2014-09-30 $8,381
2014-06-30 $8,391
2014-03-31 $8,072
2013-12-31 $8,141
2013-09-30 $8,181
2013-06-30 $8,234
2013-03-31 $8,277
2012-12-31 $8,327
2012-09-30 $5,621
2012-06-30 $4,393
2012-03-31 $4,402
2011-12-31 $4,418
2011-09-30 $4,417
2011-06-30 $4,211
2011-03-31 $4,218
2010-12-31 $4,234
2010-09-30 $3,266
2010-06-30 $3,288
2010-03-31 $3,510
2009-12-31 $3,532
2009-09-30 $3,556
2009-06-30 $3,579
2009-03-31 $3,600
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $11.598B $12.140B
DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $17.097B 10.34
Quest Diagnostics (DGX) United States $15.557B 16.08
Encompass Health (EHC) United States $8.513B 21.79
Chemed (CHE) United States $8.407B 26.06
Elanco Animal Health (ELAN) United States $8.149B 21.14
Option Care Health (OPCH) United States $4.971B 18.82
RadNet (RDNT) United States $4.259B 88.69
Amedisys (AMED) United States $3.144B 22.27
LifeStance Health (LFST) United States $2.217B 0.00
Astrana Health (ASTH) United States $2.112B 28.55
Addus HomeCare (ADUS) United States $1.785B 25.54
U.S Physical Therapy (USPH) United States $1.515B 40.54
Pennant (PNTG) United States $0.681B 35.97
Aveanna Healthcare Holdings (AVAH) United States $0.521B 0.00
Atai Life Sciences (ATAI) Germany $0.273B 0.00
Daxor (DXR) United States $0.046B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.027B 0.00
ATI Physical Therapy (ATIP) United States $0.022B 0.00
Psychemedics (PMD) United States $0.016B 0.00
Ontrak (OTRK) United States $0.013B 0.00
Novo Integrated Sciences (NVOS) United States $0.009B 0.00
IMAC Holdings (BACK) United States $0.003B 0.00